Menu
Request a demo

Our products

An agile launch execution platform, with full visibility across countries and functions.
A collaborative platform for teams who plan reimbursements and HTA activities.
A collaborative platform designed to manage pharmaceutical tenders across countries.
A capability management platform that unifies capabilities, resources, and assessment.
Manage your entire pipeline. Track every move. Stay ahead, from discovery to launch.

Our expertise

Launch Readiness

Market Access

Tender Management

Featured Post

6 Pharma Trends for 2025: Trump’s Return, AI Breakthroughs, and Market Access Challenges

  • Andre Moa
  • 21 Jan 2025
  • 21 minute read

Pharma is facing a new set of launch, market access and strategic challenges as the pandemic has changed some market characteristics for good.

Read more

Latest posts

Launch Readiness 2025: What this year holds in store for pharma product launches

Pharma innovation stays strong, but market access barriers persist. Discover key trends and strategies in our Launch Readiness 2025 report.

Read more

2024 New Drug Approvals: Key FDA and EMA approvals, breakthroughs and market trends

Discover key FDA & EMA drug approvals of 2024, breakthrough innovations, and market trends. Explore what these approvals reveal about the pharma industry's future.

Read more

Market Access 2025: Navigating the emerging HTA and drug reimbursement challenges

Discover insights from 'Market Access 2025' on overcoming HTA and drug reimbursement challenges. Learn strategies to navigate evolving market access hurdles.

Read more

Launch Readiness 2024: A fresh look at key trends affecting pharma product launches

Revitalized US approvals and thriving innovation are positive signs for new medicines this year. However, our Launch Readiness 2024 guide shows that cost and value remain critical to launch success.

Read more

Market Access 2023: New Report on key challenges in HTA and reimbursement

As market access barriers proliferate, digitally enabled alignment is key to optimising new drug uptake.

Read more

Launch Readiness 2023: Key trends impacting pharma product launches

Our Launch Readiness 2023 report examines the prospects and challenges for new medicines entering the market in the shadow of COVID-19.

Read more

New Report: Launch Readiness 2022 - How to address key trends and challenges

With COVID-19 driving innovation and agility, 2022 promises another rich crop of pharma launches. Closer cost-benefit scrutiny demands carefully differentiated value.

Read more

Rethinking Launch Readiness in 2021: The New Normal in the Shadow of COVID

COVID-19 has intensified launch challenges facing new drugs. R&D pipelines and regulatory approvals continue to deliver innovation and commercial promise.

Read more

The Ultimate Guide to Launch Readiness in 2019

Pharmaceutical companies must embrace pioneering new product launch software if they really want to optimise launch readiness to capitalise on renewed innovation and R&D productivity.

Read more

A 360˚ view of launch timelines will ease you into the market

Close attention to launch timelines and status will help save you from stumbling at the final hurdle to successful pharma market entry.

Read more

Pharma launch planning should be focused on strategy, not data management

Making the most of pharma launch planning includes ensuring that launch team members are focused on strategic objectives, not data collection and processing.

Read more

Why you need a consistent launch readiness framework

A launch readiness framework is a must to handle pharma market access challenges. You need the tools to ensure a living framework is embedded enterprise wide.

Read more

Recent Posts

Most Popular Posts

Categories

Get our latest
posts in your inbox

TRiBECA Knowledge needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Notice.